SPOTLIGHT -
Strategic Alliance Formed to Advance RNAi Therapeutics for Infectious Diseases
Alnylam Pharmaceuticals announces exclusive licensing agreement with Vir Biotechnology for the development and commercialization of RNA Interference therapeutics for infectious diseases.
Read More